GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kaken Pharmaceutical Co Ltd (OTCPK:KKPCF) » Definitions » Shiller PE Ratio

Kaken Pharmaceutical Co (Kaken Pharmaceutical Co) Shiller PE Ratio : 6.41 (As of May. 24, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Kaken Pharmaceutical Co Shiller PE Ratio?

As of today (2024-05-24), Kaken Pharmaceutical Co's current share price is $22.30. Kaken Pharmaceutical Co's E10 for the quarter that ended in Dec. 2023 was $3.48. Kaken Pharmaceutical Co's Shiller PE Ratio for today is 6.41.

The historical rank and industry rank for Kaken Pharmaceutical Co's Shiller PE Ratio or its related term are showing as below:

KKPCF' s Shiller PE Ratio Range Over the Past 10 Years
Min: 8.02   Med: 12.33   Max: 21.95
Current: 8.61

During the past years, Kaken Pharmaceutical Co's highest Shiller PE Ratio was 21.95. The lowest was 8.02. And the median was 12.33.

KKPCF's Shiller PE Ratio is ranked better than
91.74% of 533 companies
in the Drug Manufacturers industry
Industry Median: 24.7 vs KKPCF: 8.61

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Kaken Pharmaceutical Co's adjusted earnings per share data for the three months ended in Dec. 2023 was $0.478. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is $3.48 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Kaken Pharmaceutical Co Shiller PE Ratio Historical Data

The historical data trend for Kaken Pharmaceutical Co's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kaken Pharmaceutical Co Shiller PE Ratio Chart

Kaken Pharmaceutical Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.89 11.49 10.04 9.42 -

Kaken Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.42 9.09 8.80 8.40 -

Competitive Comparison of Kaken Pharmaceutical Co's Shiller PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Kaken Pharmaceutical Co's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kaken Pharmaceutical Co's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kaken Pharmaceutical Co's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Kaken Pharmaceutical Co's Shiller PE Ratio falls into.



Kaken Pharmaceutical Co Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Kaken Pharmaceutical Co's Shiller PE Ratio for today is calculated as

Shiller PE Ratio=Share Price/ E10
=22.30/3.48
=6.41

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kaken Pharmaceutical Co's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Kaken Pharmaceutical Co's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.478/106.8000*106.8000
=0.478

Current CPI (Dec. 2023) = 106.8000.

Kaken Pharmaceutical Co Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 0.533 95.700 0.595
201406 0.611 98.000 0.666
201409 0.673 98.500 0.730
201412 0.802 97.900 0.875
201503 0.505 97.900 0.551
201506 1.229 98.400 1.334
201509 1.242 98.500 1.347
201512 1.518 98.100 1.653
201603 0.216 97.900 0.236
201606 1.329 98.100 1.447
201609 1.341 98.000 1.461
201612 1.361 98.400 1.477
201703 0.874 98.100 0.952
201706 1.206 98.500 1.308
201709 1.207 98.800 1.305
201712 1.315 99.400 1.413
201803 0.511 99.200 0.550
201806 0.910 99.200 0.980
201809 1.077 99.900 1.151
201812 1.212 99.700 1.298
201903 0.799 99.700 0.856
201906 1.126 99.800 1.205
201909 1.124 100.100 1.199
201912 1.413 100.500 1.502
202003 0.911 100.300 0.970
202006 0.913 99.900 0.976
202009 0.833 99.900 0.891
202012 0.930 99.300 1.000
202103 0.593 99.900 0.634
202106 0.797 99.500 0.855
202109 0.803 100.100 0.857
202112 0.818 100.100 0.873
202203 -0.155 101.100 -0.164
202206 0.574 101.800 0.602
202209 0.568 103.100 0.588
202212 0.630 104.100 0.646
202303 -0.740 104.400 -0.757
202306 0.474 105.200 0.481
202309 0.279 106.200 0.281
202312 0.478 106.800 0.478

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Kaken Pharmaceutical Co  (OTCPK:KKPCF) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Kaken Pharmaceutical Co Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Kaken Pharmaceutical Co's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Kaken Pharmaceutical Co (Kaken Pharmaceutical Co) Business Description

Traded in Other Exchanges
Address
28-8, Honkomagome 2-chome, Bunkyo-ku, Tokyo, JPN, 1138650
Kaken Pharmaceutical Co is a specialty and generic drug manufacturing company. The company organizes its segments between pharmaceutical and real estate activities. The pharmaceutical segment consists of pharmaceutical drugs, medical devices, and agrochemicals. In the real estate segment, the majority of revenue is generated through commercial facility rental fees. Sales in Japan constitute more than 90% of revenue. Kaken considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Kaken Pharmaceutical Co (Kaken Pharmaceutical Co) Headlines

No Headlines